Valuation : Spyre Therapeutics, Inc.

Market Cap 7.99B 6.88B 6.52B 5.91B 11.08B 763B 11.14B 77.4B 29.77B 388B 30B 29.34B 1,227B P/E 2026 *
-31x
P/E 2027 * -24.7x
Enterprise Value 7.53B 6.49B 6.15B 5.57B 10.45B 720B 10.5B 72.99B 28.07B 366B 28.29B 27.67B 1,157B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.4%
Yield 2026 *
-
Yield 2027 * -
1 day+2.13%
1 week+1.82%
Current month+1.42%
1 month-12.96%
3 months+12.14%
6 months+124.20%
Current year+176.56%
1 week 85
Extreme 85.0001
92.1
1 month 84
Extreme 84
110.18
Current year 28
Extreme 28
110.18
1 year 14.5
Extreme 14.505
110.18
3 years 8.43
Extreme 8.43
110.18
5 years 2.66
Extreme 2.66
212.5
10 years 2.66
Extreme 2.66
300
Manager TitleAgeSince
Chief Executive Officer 36 27/11/2023
Director of Finance/CFO 49 01/09/2023
Chief Tech/Sci/R&D Officer - 27/11/2023
Director TitleAgeSince
Director/Board Member 36 27/11/2023
Director/Board Member 39 22/06/2023
Director/Board Member 36 22/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 A Sell

Chief Financial Officer

-18,232 0.0210%
9/2/26 A Exercice

General Counsel

1,200 0.0014%
9/1/26 A Sell

Chief Executive Officer

-15,000 0.0173%
Change 5-day change 1-year change 3-year change Capi.($)
+2.13%+1.82%+478.91%+554.15% 7.99B
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.05%-2.47%+75.48%+278.14% 27.84B
Weighted average by Cap. -0.48%-2.69%+44.10%+181.66%

Financials

2026 *2027 *
Net sales - -
Net income -260M -224M -212M -192M -360M -24.82B -362M -2.52B -968M -12.63B -976M -954M -39.91B -336M -290M -274M -249M -466M -32.12B -469M -3.26B -1.25B -16.34B -1.26B -1.23B -51.63B
Net Debt -456M -393M -372M -337M -632M -43.53B -635M -4.41B -1.7B -22.14B -1.71B -1.67B -69.97B -565M -487M -461M -418M -784M -53.98B -788M -5.47B -2.11B -27.46B -2.12B -2.08B -86.78B
Logo Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).
Employees
125
Date Price Change Volume
11/09/26 $90.60 +2.13% 886,055
10/09/26 $88.71 +2.05% 902,458
09/09/26 $86.93 -4.25% 1,005,796
08/09/26 $90.79 +2.03% 1,249,656
04/09/26 $88.98 +1.98% 803,857
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
90.60USD
Average target price
120.08USD
Spread / Average Target
+32.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SYRE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!